^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL23A (Interleukin 23 Subunit Alpha)

    i
    Other names: IL23A, Interleukin 23 Subunit Alpha, SGRF, IL23P19, IL-23A, IL-23, P19, Interleukin-Six, G-CSF Related Factor, Interleukin 23, Alpha Subunit P19, Interleukin-23 Subunit Alpha, Interleukin-23 Subunit P19, IL-23 Subunit Alpha, IL-23p19, IL-23-A, JKA3 Induced Upon T-Cell Activation, Interleukin 23 P19 Subunit
    4d
    Evaluation of 3D biomimetic microcarriers for enhancing therapeutic efficacy of human umbilical cord mesenchymal stem cells in psoriasis treatment. (PubMed, Front Immunol)
    Transcriptomic analysis revealed that 3D-hUC-MSCs modulated signaling pathways associated with inflammation and innate immune responses. Our findings suggest that the 3D microcarrier-bioreactor system holds promise as a strategy to enhance the therapeutic potential of hUC-MSCs, particularly in the treatment of immune-mediated disorders such as psoriasis.
    Journal
    |
    IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
    4d
    IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? (PubMed, J Inflamm Res)
    Although all three agents demonstrate high and durable effectiveness, real-world data suggest subtle intraclass differences, with guselkumab and risankizumab often achieving faster or deeper early responses, and tildrakizumab offering greater dosing flexibility with comparable long-term persistence in selected patient profiles. Overall, IL-23 blockade has evolved from a highly effective trial-based strategy into a versatile and reliable long-term therapeutic approach capable of addressing unmet needs in routine clinical practice.
    Review • Journal
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    Ilumya (tildrakizumab-asmn)
    5d
    Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities. (PubMed, Inflammopharmacology)
    This review supports early screening, metabolic monitoring, and lifestyle changes as critical components of long-term psoriatic therapy. Recognising psoriasis as a systemic condition is critical for improving overall patient outcomes, lowering morbidity, and avoiding long-term consequences.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha)
    9d
    Engineered exosome nanovesicles for delivery of antibodies to treat inflammatory bowel disease. (PubMed, Nat Commun)
    This dual-action strategy significantly alleviates IBD, prevents complications like intestinal fibrosis and colitis-associated colorectal cancer, and shows p53-dependent efficacy in carcinogenesis prevention. These findings highlight PrEXO-a23 as a promising nanotherapeutic platform for durable immune reprogramming and long-term IBD management.
    Journal
    |
    IL23A (Interleukin 23 Subunit Alpha)
    10d
    Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia. (PubMed, Int J Mol Sci)
    Fraction-specific analyses showed stronger induction of IL-23R and IL-23R complex expression in PF compared with RF. These findings identify an intraclonal bias toward IL-23 responsiveness in the CLL cells with a phenotype of recently divided, tissue-emigrated cells and suggest the IL-23/IL-23R axis as a potential therapeutic target.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD5 (CD5 Molecule) • IL23A (Interleukin 23 Subunit Alpha) • IL15 (Interleukin 15)
    17d
    Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors. (PubMed, Dermatol Reports)
    PE has been reported with anti-tumor necrosis factor (TNF)-α, anti-interleukin (IL)-17, and more recently with anti-IL-23 agents such as risankizumab, tildrakizumab, and guselkumab, with an estimated incidence of 1-3% among psoriatic patients treated with biologics, likely underestimated. Herein, we report the successful use of upadacitinib, an oral selective Janus kinase (JAK)-1 inhibitor approved for both psoriatic arthritis and atopic dermatitis, in the management of a PE induced by guselkumab. [...].
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL23A (Interleukin 23 Subunit Alpha)
    |
    Ilumya (tildrakizumab-asmn)
    17d
    Inflammatory profile associated with hyperglycemia in children with type 1 diabetes. (PubMed, J Diabetes Complications)
    A broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CCL27 (C-C Motif Chemokine Ligand 27) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • LIF (LIF Interleukin 6 Family Cytokine)
    19d
    Enhanced Anti-Psoriasis Efficacy of Curcumin via Optimized Nanostructured Lipid Carrier-Embedded Nanogel System. (PubMed, Chem Biodivers)
    Histological evaluation further confirmed restoration of normal skin structure in treated animals. Overall, the CUR-SLN-loaded nanogel represents a promising and safer topical therapeutic strategy for psoriasis, supporting its potential for further clinical development.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IFNA1 (Interferon Alpha 1)
    23d
    Study on the Mechanism of Treatment Response to IL-23 Monoclonal Antibody in Patients with Inflammatory Bowel Disease (ChiCTR2500111751)
    P=N/A, N=30, Not yet recruiting, Shenjing Hospital of China Medical University; Shengjing Hospital of China Medical University
    New trial
    |
    IL23A (Interleukin 23 Subunit Alpha)
    23d
    Signaling pathways and molecular mechanisms of lupeol in colorectal cancer: A comprehensive review. (PubMed, J Ayurveda Integr Med)
    Recent advances in nano-based delivery systems and the invention of lupeol derivatives have increased its bioavailability and bioactivity, making it a promising candidate for CRC treatment. This study seeks to inspire additional research into lupeol's significance as a nutraceutical intervention in CRC by integrating current knowledge and investigating novel techniques to increase its clinical efficacy.
    Review • Journal
    |
    IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL23A (Interleukin 23 Subunit Alpha)
    25d
    A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Mage Biologics
    New P1/2 trial
    |
    IL23A (Interleukin 23 Subunit Alpha)
    26d
    Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery. (PubMed, J Immunother Cancer)
    These results demonstrate the utility of a modular NP design for systematic screening of signal 2/3 delivery to melanoma in vivo and highlight the benefit of in-depth profiling via spatial proteomics to evaluate local antitumor immune responses. The results provide insight into the mechanisms underpinning this therapeutic reprogramming strategy, emphasizing the relationship between signal 2/3 NPs and their ability to drive signal 1 for productive antitumor responses in vivo.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL23A (Interleukin 23 Subunit Alpha) • IL15 (Interleukin 15) • TNFSF4 (TNF Superfamily Member 4) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)